Artiva Biotherapeutics, Inc. ARTV Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s other commercial liabilities?
- Artiva Biotherapeutics, Inc. (ARTV) reported other commercial liabilities of $5.56M in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s other commercial liabilities changed year-over-year?
- Artiva Biotherapeutics, Inc.'s other commercial liabilities decreased by 12.8% year-over-year, from $6.38M to $5.56M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s other commercial liabilities?
- Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s other commercial liabilities has grown at a 9.4% compound annual growth rate (CAGR), from $8.02M to $9.6M.